Clinical Trial Update: Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adjuvant pyrotinib in combination with trastuzumab for HER2-positive invasive breast cancer; not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING